These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 15841378

  • 1. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
    [Abstract] [Full Text] [Related]

  • 3. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 4. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
    Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA.
    Cancer Chemother Pharmacol; 2005 Aug 15; 56(2):115-25. PubMed ID: 15791458
    [Abstract] [Full Text] [Related]

  • 5. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 6. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
    Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.
    Cancer Res; 2005 Aug 01; 65(15):6967-75. PubMed ID: 16061682
    [Abstract] [Full Text] [Related]

  • 7. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 8. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM, Fiebig HH, Stinson SF, Sausville EA.
    Anticancer Drugs; 2004 Apr 15; 15(4):377-87. PubMed ID: 15057143
    [Abstract] [Full Text] [Related]

  • 9. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
    Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3749-55. PubMed ID: 14506167
    [Abstract] [Full Text] [Related]

  • 10. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P.
    Oncogene; 2000 Aug 24; 19(36):4125-33. PubMed ID: 10962573
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 24; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 14. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR, Bradley MS, Jin X, Lin J.
    Gynecol Oncol; 2005 Feb 27; 96(2):381-8. PubMed ID: 15661225
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
    Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA.
    Cancer Res; 2001 May 15; 61(10):4003-9. PubMed ID: 11358818
    [Abstract] [Full Text] [Related]

  • 16. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2004 Dec 01; 10(23):8077-84. PubMed ID: 15585643
    [Abstract] [Full Text] [Related]

  • 17. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y, Ding J.
    Ai Zheng; 2004 Aug 01; 23(8):968-74. PubMed ID: 15301726
    [Abstract] [Full Text] [Related]

  • 18. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.
    J Natl Cancer Inst; 2003 Nov 05; 95(21):1624-33. PubMed ID: 14600095
    [Abstract] [Full Text] [Related]

  • 19. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
    Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G.
    Cancer Res; 2003 Dec 01; 63(23):8393-9. PubMed ID: 14679001
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.